How to Differentiate Your ABA Practice in a Crowded Market
The ABA field is more crowded than it was five years ago, and the bar for standing out has moved. The phrases
EarliPoint Health Launches Project ALIGN to Advance Objective Measurement and Outcomes in Autism Care
Learn More →The ABA field is more crowded than it was five years ago, and the bar for standing out has moved. The phrases
For many families, the Fourth of July means backyard barbecues, sparklers, and fireworks. For families of children with autism, it can mean
Every six months or so, your practice has to prove that a child is making progress — or risk a reduced authorization,
New feature advances EarliPoint’s vision of delivering objective intelligence across the autism care journey PLYMOUTH, MN — June 16, 2026 — EarliPoint
Ask ten BCBAs which assessment to use and you’ll get ten answers — usually because they’re answering slightly different questions. The VB-MAPP,
You’ve made the pasta again. Same brand. Same shape. Cooked the exact same way, served in the exact same bowl. You already
The Vineland-3 is the one of the most widely used adaptive behavior assessments in autism and developmental evaluation — but it isn’t
The ADOS-2 generates a lot of numbers. Algorithm totals, domain scores, cutoff classifications, and calibrated severity scores. For clinicians who administer the
One of the most consequential decisions in an ADOS-2 evaluation happens before the first activity begins: selecting the right module. ADOS-2 contains
Parades, festivals, and community celebrations are a hallmark of summer holidays. For many families, they are something to look forward to. For
Families don’t experience progress as a graph. They experience it as trust or doubt — a sense that therapy is working, or
The VB-MAPP is one of the most widely used assessments in applied behavior analysis, and for good reason. It gives BCBAs a
Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.
Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.
Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.